JP2017506234A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506234A5
JP2017506234A5 JP2016550786A JP2016550786A JP2017506234A5 JP 2017506234 A5 JP2017506234 A5 JP 2017506234A5 JP 2016550786 A JP2016550786 A JP 2016550786A JP 2016550786 A JP2016550786 A JP 2016550786A JP 2017506234 A5 JP2017506234 A5 JP 2017506234A5
Authority
JP
Japan
Prior art keywords
antibody
seq
drug conjugate
amino acid
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016550786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506234A (ja
JP6616776B2 (ja
Filing date
Publication date
Priority claimed from GB201402009A external-priority patent/GB201402009D0/en
Application filed filed Critical
Publication of JP2017506234A publication Critical patent/JP2017506234A/ja
Publication of JP2017506234A5 publication Critical patent/JP2017506234A5/ja
Application granted granted Critical
Publication of JP6616776B2 publication Critical patent/JP6616776B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016550786A 2014-02-06 2015-02-04 抗体−薬物複合体及び免疫毒素 Active JP6616776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1402009.3 2014-02-06
GB201402009A GB201402009D0 (en) 2014-02-06 2014-02-06 Antibody-drug conjugates and immunotoxins
PCT/EP2015/052342 WO2015118031A2 (en) 2014-02-06 2015-02-04 Antibody-drug conjugates and immunotoxins

Publications (3)

Publication Number Publication Date
JP2017506234A JP2017506234A (ja) 2017-03-02
JP2017506234A5 true JP2017506234A5 (ja�@�@) 2018-03-15
JP6616776B2 JP6616776B2 (ja) 2019-12-04

Family

ID=50390520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550786A Active JP6616776B2 (ja) 2014-02-06 2015-02-04 抗体−薬物複合体及び免疫毒素

Country Status (12)

Country Link
US (1) US10004812B2 (ja�@�@)
EP (1) EP3102606B1 (ja�@�@)
JP (1) JP6616776B2 (ja�@�@)
KR (1) KR102342934B1 (ja�@�@)
CN (1) CN105980411B (ja�@�@)
CA (1) CA2937600C (ja�@�@)
DK (1) DK3102606T3 (ja�@�@)
ES (1) ES2701188T3 (ja�@�@)
GB (1) GB201402009D0 (ja�@�@)
HU (1) HUE040517T2 (ja�@�@)
PL (1) PL3102606T3 (ja�@�@)
WO (1) WO2015118031A2 (ja�@�@)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
KR20180090290A (ko) 2015-12-04 2018-08-10 시애틀 지네틱스, 인크. 사차화 튜불리신 화합물들의 컨쥬게이트들
WO2018187158A1 (en) * 2017-04-07 2018-10-11 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents
US20200165350A1 (en) * 2017-06-01 2020-05-28 Health Research, Inc. Strong potentiation of immune checkpoint blockade therapy of cancer by combination with endoglin-targeting therapy
PL3666787T3 (pl) * 2017-08-10 2024-04-29 Sumitomo Pharma Co., Ltd. Koniugaty przeciwciało-lek zawierające pochodną hemiasterliny
EP4321523A3 (en) 2017-08-10 2024-04-24 Sumitomo Pharma Co., Ltd. Hemiasterlin derivatives and antibody-drug conjugates including same
JP2017214419A (ja) * 2017-08-18 2017-12-07 学校法人関西医科大学 白血病改善剤
EP3621652A4 (en) * 2017-12-31 2021-01-13 Hangzhou DAC Biotech Co, Ltd CONJUGATE OF ANALOGUE OF TUBULYSIN WITH BRANCHED LINKS
CN113195164B (zh) 2018-12-18 2023-08-18 3M创新有限公司 带涂层磨料制品及制备带涂层磨料制品的方法
JP7432531B2 (ja) 2019-02-13 2024-02-16 住友ファーマ株式会社 システイン残基を有するヘミアスタリン誘導体
JP7560255B2 (ja) * 2019-02-13 2024-10-02 住友ファーマ株式会社 ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
WO2020166592A1 (ja) 2019-02-13 2020-08-20 大日本住友製薬株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
EP4716750A1 (en) 2023-05-23 2026-04-01 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
TWI905962B (zh) * 2023-10-04 2025-11-21 台耀化學股份有限公司 用於綴合之化合物、綴合物及包含其之醫藥組成物
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025141153A1 (en) * 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US7097836B1 (en) * 2002-10-23 2006-08-29 Health Research, Inc. Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
AU2008224988A1 (en) * 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
WO2008138561A1 (en) 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CN102596922A (zh) * 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
ES2781523T3 (es) 2012-07-12 2020-09-02 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
WO2015113760A1 (en) 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation

Similar Documents

Publication Publication Date Title
JP2017506234A5 (ja�@�@)
JP2017506630A5 (ja�@�@)
JP2020509027A5 (ja�@�@)
JP2016523810A5 (ja�@�@)
JP2019535254A5 (ja) 抗pd−l1抗体および変異型
JP2020525542A5 (ja�@�@)
JP2017534256A5 (ja�@�@)
JP2019532056A5 (ja�@�@)
JP2016538318A5 (ja�@�@)
JP2017500028A5 (ja�@�@)
JP2017518040A5 (ja�@�@)
JP2016531915A5 (ja�@�@)
JP2015534579A5 (ja�@�@)
JP2013510868A5 (ja�@�@)
JP2020502271A5 (ja�@�@)
JP5948525B1 (ja) 癌のための併用療法
RU2018124319A (ru) Новые антитела к клаудину и способы их применения
JP2017514795A5 (ja�@�@)
JP2015509947A5 (ja�@�@)
JP2017510661A5 (ja�@�@)
JPWO2021177438A5 (ja�@�@)
JP2025510606A (ja) B7h4抗体薬物複合体及びその使用
JP2021502423A5 (ja�@�@)
JP2023509214A5 (ja�@�@)
JP2025539841A5 (ja�@�@)